This statistic shows the amount of registrations of newly diagnosed cases of stomach cancer in England in 2022, by age group. With a total of *** cases in 2022, the age group most affected by stomach cancer in terms of the number of cases was men aged 75 to 79 years. It should be noted that the number of people in England in each age group varies and is therefore not necessarily a reflection of susceptibility to this cancer.

Mortality from stomach cancer (ICD-10 C16 equivalent to ICD-9 151). To reduce deaths from stomach cancer. Legacy unique identifier: P00673

In 2019, nearly *** percent of all men, as well as more than *** percent of all women diagnosed with stomach cancer were between 65 to 69 years old. Meanwhile, only **** percent of all boys and **** percent of all girls and teens under 19 years old had the same condition.

Deaths from stomach cancer - Directly age-Standardised Rates (DSR) per 100,000 population Source: Office for National Statistics (ONS) Publisher: Information Centre (IC) - Clinical and Health Outcomes Knowledge Base Geographies: Local Authority District (LAD), Government Office Region (GOR), National, Primary Care Trust (PCT), Strategic Health Authority (SHA) Geographic coverage: England Time coverage: 2005-07, 2007 Type of data: Administrative data

ObjectivesStomach cancer is one of the leading causes of cancer death, and its epidemiologic characteristics are regionally heterogeneous worldwide. The BRICS nations (Brazil, Russian Federation, India, China, and South Africa) have markedly increasing influences on the international stage. We aim to investigate time trends in stomach cancer mortality among the BRICS countries from 1982 to 2021.MethodsData for this study were obtained from the Global Burden of Disease (GBD) 2021 public dataset to investigate the deaths, all-age mortality rate, and age-standardized mortality rate (ASMR) of stomach cancer. The age-period-cohort (APC) model was employed to estimate net drift, local drift, age-specific curves, and period (cohort) relative risks, and the Bayesian generalized linear model was employed to evaluate the relationship between food intake and mortality rate.ResultsIn 2021, there were approximately 572,000 stomach cancer deaths across the BRICS, accounting for 59.9% of global death. Russian Federation exhibited the most significant reduction in ASMR of stomach cancer among the BRICS. In contrast, China continued to report the highest number of stomach cancer deaths. The risk of mortality associated with stomach cancer exhibited a marked increase with advancing age, both within these countries and at the global level. PUFA, sodium, calcium and trans fat may have an impact on the mortality rate of stomach cancer. Favorable trends in period and birth cohort effects were observed in these five nations over the past decades.ConclusionBRICS countries have made varying progress in reducing stomach cancer mortality. Given the diverse environments, it is recommended to progressively develop customized stomach cancer prevention strategies, utilizing available resources. Healthcare services should be extended to all age groups, with a particular emphasis on vulnerable populations.

Years of Life Lost (YLL) as a result of death from stomach cancer - Directly age-Standardised Rates (DSR) per 100,000 population Source: Office for National Statistics (ONS) Publisher: Information Centre (IC) - Clinical and Health Outcomes Knowledge Base Geographies: Local Authority District (LAD), Government Office Region (GOR), National, Primary Care Trust (PCT), Strategic Health Authority (SHA) Geographic coverage: England Time coverage: 2005-07, 2007 Type of data: Administrative data

BackgroundStomach cancer is a significant health problem in many countries. But healthcare needs of adolescents and young adults (AYAs) stomach cancer patients have been historically neglected. An accurate appraisal of the burden of AYA stomach cancer is crucial to formulating effective preventive strategies. In this study, we report the most recent estimates of AYA stomach cancer burden concerning socio-demographic index (SDI) in 204 countries and territories between 1990 and 2019.MethodsEstimates from the Global Burden of Disease study 2019 were used to analyze incidence, mortality, and disability-adjusted life years (DALYs) due to AYA stomach cancer at global, regional, and national levels. Association between AYA stomach cancer burden and SDI were investigated. All estimates are reported as absolute numbers and age-standardized rates, which were standardized to the GBD world population and reported per 100,000 population.ResultsIn 2019, there were 49,000 incident cases, 27,895 deaths, and 1.57 million DALYs due to AYA stomach cancer globally. The highest age-standardized incidence rate occurred in East Asia [2.42 (women) and 4.71 (men) per 100,000 person-years] and high-income Asia Pacific [3.16 (women) and 2.61 (men) per 100,000 person-years]. Age-standardized death [1.53 (women) and 2.65 (men) per 100,000 person-years] and DALY [150.96 (women) and 87.13 (men) per 100,000 person-years] rates were highest in Oceania. Compared with 1990, in 2019 more than 1,075 more incident cases of AYA stomach cancer were estimated with a decrease of 7,784 deaths. Despite the increase in absolute number of incident cases, the worldwide age-standardized rates of AYA stomach cancer (incidence, deaths, and DALYs) have declined since 1990. The drop in the disease burden was associated with an improved SDI. Globally, 24.41% of the age-standardized DALYs were attributable to a high-sodium diet in both sexes combined, and 0.57% of the age-standardized DALYs were attributable to smoking in men.ConclusionThe global burden of AYA stomach cancer is substantial, especially in developing regions. Capacity-building activities for AYA stomach cancer will benefit the younger generation and population health worldwide.

This dataset is designed for the task of gastric cancer detection using advanced machine learning models. It contains clinical, demographic, diagnostic, and molecular data gathered from diverse healthcare sources, specifically focusing on gastric cancer (GC) patients. The dataset is sourced from clinical studies, medical imaging, and genomics, offering a rich collection of features that can be leveraged to identify patterns and predict cancer risks, including genetic, environmental, and lifestyle-related factors.

The dataset consists of comprehensive records from gastric cancer patients, detailing their medical history, diagnostic results, and various imaging and molecular profiles. It is particularly useful for research in AI-based detection and diagnosis of gastric cancer, as well as in predictive modeling for clinical decision-making.

This study employed a Zurich, Switzerland, specialized research cooperative dataset \cite{33}. This collection includes patient information from regional medical facilities and research labs known for cancer and molecular diagnostics. It offers varied and high-quality data from real-world stomach cancer diagnostic and clinical procedures. The data gathering procedure followed strong ethical and privacy norms to protect patient data. Gastric cancer research records were validated to ensure relevance and correctness, making them trustworthy for AI-driven medical applications. The dataset contains demographic, clinical, and molecular information important to healthcare analytics and represents the newest advances. A stable basis for AI-based stomach cancer diagnosis, this dataset allows prediction models to be tested and validated in real life.

Features The dataset includes the following columns, each representing key variables related to gastric cancer detection and patient characteristics:

Age:

Type: Numerical Description: Age of the patient at the time of diagnosis or evaluation. Gender:

Type: Categorical (Male/Female) Description: The gender of the patient. Ethnicity:

Type: Categorical Description: Ethnic background of the patient. Geographical Location:

Type: Categorical Description: The geographical location where the data was collected (e.g., country, region). Family History:

Type: Binary (Yes/No) Description: Whether the patient has a family history of cancer (Yes/No). Smoking Habits:

Type: Binary (Yes/No) Description: Whether the patient smokes (Yes/No). Alcohol Consumption:

Type: Binary (Yes/No) Description: Whether the patient consumes alcohol (Yes/No). Helicobacter Pylori Infection:

Type: Binary (Yes/No) Description: Whether the patient has a Helicobacter pylori infection, a known risk factor for gastric cancer. Dietary Habits:

Type: Categorical Description: Dietary patterns of the patient, such as high salt intake or high-fat diet. Existing Conditions:

Type: Categorical Description: Pre-existing medical conditions such as diabetes, gastritis, or hypertension. Endoscopic Images:

Type: Categorical (Normal/Abnormal) Description: Results from endoscopy imaging of the gastric mucosa. Normal or abnormal findings. Biopsy Results:

Type: Categorical (Positive/Negative) Description: The result of biopsy testing. Positive or negative for cancer. CT Scan:

Type: Categorical (Normal/Abnormal) Description: Imaging results from a CT scan used to detect potential tumors in the stomach. Mature miRNA Accession:

Type: Categorical Description: Accession number of the mature miRNA, a biomarker used in cancer diagnosis. Mature miRNA ID:

Type: Categorical Description: Identifier for the mature miRNA sequence. Target Symbol:

Type: Categorical Description: Symbol of the target gene associated with the miRNA. Target Entrez:

Type: Categorical Description: Unique Entrez Gene ID for the target gene. Target Ensembl:

Type: Categorical Description: Unique Ensembl Gene ID for the target gene. DIANA microT Score:

Type: Numerical Description: Prediction score for miRNA-target interaction based on the DIANA algorithm. ElMMo Score:

Type: Numerical Description: Confidence score for miRNA-target predictions. Microcosm Score:

Type: Numerical Description: Interaction score based on the Microcosm prediction algorithm. MiRanda Score:

Type: Numerical Description: Score representing miRNA-target alignment from the MiRanda algorithm. miRDB Score:

Type: Numerical Description: Confidence score from the miRDB database indicating the strength of miRNA-target interaction. PicTar Score:

Type: Numerical Description: Predicted miRNA-target interaction score from the PicTar algorithm. PITA Score:

Type: Numerical Description: Prediction score based on target accessibility. TargetScan Score:

Type: Numerical Description: miRNA target prediction score from the TargetScan algorithm. Predicted Sum:

Type: Numerical Description: Aggregated prediction confidence score across multiple algorithms. All...

This publication reports on newly diagnosed cancers registered in England during 2022. It includes this summary report showing key findings, spreadsheet tables with more detailed estimates, and a methodology document. Cancer registration estimates are provided for: • Incidence of cancer using groupings that incorporate both the location and type of cancer by combinations of gender, age, deprivation, and stage at diagnosis (where appropriate) for England, former Government office regions, Cancer alliances and Integrated care boards • Incidence and mortality (using ICD-10 3-digit codes) by gender and age group for England, former Government office regions, Cancer alliances and Integrated care boards This publication will report on 2022 cancer registrations only, trends will not be reported as the required re-stated populations for 2012 to 2020 are not expected to be published by the Office of National Statistics (ONS) until Winter 2024.

Table S3(A-D) shows country- and sex-specific data on new cases, person-years, crude incidence rates (CR), age-standardized incidence rates (ASIR), confidence intervals (LCIa, UCIa), and variance for non-cardia gastric cancer (NCGC) and cardia gastric cancer (CGC) in the whole and young (

Discover the latest market analysis on stomach cancer drugs, revealing a booming market driven by rising incidence and innovative therapies. Explore key players, regional trends, and future growth projections for this dynamic sector. Learn about the challenges and opportunities shaping the future of stomach cancer treatment.

In 2021, 13.7 males and 6.7 females per 100,000 population in England were registered as new cases of stomach cancer. Overall, the rate of new stomach cancer diagnoses rate has decreased over the analyzed years. This statistic shows the rate of newly diagnosed cases of stomach cancer per 100,000 population in England from 1995 to 2021, by gender.

Additional file 12: Table S1. The incident cases, age-standardized incidence and temporal trends of gastric cancer in countries from 1990 to 2019. Table S2. Joinpoint regression analysis of gastric cancer incidence in countries from 1990 to 2019. Table S3. Joinpoint regression analysis of gastric cancer incidence of annual percentage change (APC) in territories from 1990 to 2019. Table S4. Joinpoint regression analysis of gastric cancer incidence of average annual percentage change (AAPC) in territories from 1990 to 2019.

Table C. Age-specific stomach cancer deaths and the corresponding population, birth cohort and year of survey in the period 1987-2016 in Lithuania. Men

BackgroundColon cancer, esophageal cancer, and stomach cancer are the common causes of morbidity and mortality in China, Japan, the US., and India. The current study aims to assess and compare secular trends of the mortality of gastrointestinal cancers during the period, 1990–2017 in age-specific, time period, and birth cohort effects.MethodWe used the Joinpoint model to collect age-standardized mortality rates (ASMRs) for four countries. We designed an age-period-cohort (APC) analysis to estimate the independent effects on the mortality of three types of cancers.ResultThe Joinpoint model shows that in addition to the death rate of esophageal cancer in Japan, the ASMR of esophageal cancer and stomach cancer in other countries declined rapidly. The APC analysis presented a similar pattern of age effect between four countries for colon cancer and stomach cancer, which increased from 20 to 89 age groups. Differently, the period effect rapidly increased for esophageal cancer and stomach cancer in the US, and the period effect in China presented a declining volatility, showing its highest value in 2007. In future, highest mortality trends are likely to occur in China.ConclusionTherefore, the obvious increase in colon cancer recommended that earlier tactics must be performed to reduce mortality from specific causes from 2018 to 2027.

In 2020, the mortality rate for stomach cancer was 6.2 per 100,000 population among males in Canada. This statistic displays the age-standardized mortality rate of stomach cancers among males in Canada between 1988 and 2020, with forecasts from 2021 to 2023.

BackgroundNotable geographic and temporal variations in the prevalence and genotypes of Helicobacter pylori, in relation to gastric pathologies, have been observed; however, their significance and trends in African populations is scarcely described. The aim of this study, was to investigate the association of H. pylori and its respective CagA and vacuolating cytotoxin A (VacA) genotypes with gastric adenocarcinoma, and to describe the trends of H. pylori genotypes over an 8-year period (2012–2019).Materials and methodsA total of 286 samples of gastric cancer cases and benign controls (one-to-one matching), from three main cities in Kenya, between 2012 and 2019 were included. Histologic evaluation, and CagA and VacA genotyping using PCR, was performed. Distribution of H. pylori genotypes was presented in proportions. To determine association, a univariate analysis was conducted using a Wilcoxon rank sum test for continuous variables, and a Chi-squared test or Fisher’s exact test for categorical data.ResultsThe VacA s1m1 genotype was associated with gastric adenocarcinoma, {odds ratio (OR) = 2.68 [confidence interval (CI) of 95%: 0.83–8.65]; p = 0.108}, whilst VacA s2m2 was associated with a reduced probability of gastric adenocarcinoma [OR = 0.23 (CI 95%: 0.07–0.78); p = 0.031]. No association between cytotoxin associated gene A (CagA) and gastric adenocarcinoma was observed.ConclusionOver the study period, an increase in all genotypes of H. pylori was seen, and although no predominant genotype was noted, there was significant year-to-year variation, with VacA s1 and VacA s2 showing the greatest variation. VacA s1m1 and VacA s2m2 were associated with increased, and reduced risk of gastric cancer, respectively. Intestinal metaplasia and atrophic gastritis did not appear to be significant in this population.

The global Stomach and Gastric Cancer Treatment market is poised for significant expansion, projected to reach an estimated market size of approximately $15,500 million by 2025, with a robust Compound Annual Growth Rate (CAGR) of XX% anticipated between 2025 and 2033. This growth trajectory is primarily propelled by advancements in targeted therapies and immunotherapies, which are revolutionizing treatment paradigms. The increasing incidence of gastric cancer, particularly in certain demographic groups and regions, coupled with a growing awareness and early detection initiatives, further fuels market demand. Key market drivers include the development of novel therapeutic agents, such as Programmed Cell Death Protein 1 (PD-1) inhibitors and Human Epidermal Growth Factor Receptor (HER2) antagonists, offering improved efficacy and reduced side effects compared to traditional chemotherapy. The expanding healthcare infrastructure, particularly in emerging economies, and the growing preference for specialized cancer treatment centers like hospitals and clinics also contribute to market dynamism. Despite the optimistic outlook, certain restraints may influence the market's pace. High treatment costs associated with advanced therapies and the potential for side effects can pose challenges to widespread adoption, especially in resource-limited settings. Stringent regulatory approval processes for new drugs can also impact market entry timelines. However, ongoing research and development efforts, strategic collaborations between pharmaceutical giants and biotechnology firms, and the increasing focus on personalized medicine are expected to mitigate these restraints. The market is segmented by therapeutic type, with PD-1 inhibitors and HER2 antagonists holding substantial shares due to their proven efficacy. Geographically, North America and Europe currently dominate the market, driven by sophisticated healthcare systems and high R&D investments. Nevertheless, the Asia Pacific region, with its large patient pool and growing healthcare expenditure, presents substantial growth opportunities for market players. This comprehensive report delves into the dynamic landscape of Stomach Cancer and Gastric Cancer Treatment, providing in-depth analysis and strategic insights for stakeholders. The global market, estimated to be worth over 15,000 million USD, is characterized by intense research and development, evolving therapeutic approaches, and significant investment from leading pharmaceutical giants. The report offers a detailed examination of treatment modalities, market segmentation, regional trends, and future projections, empowering businesses to navigate this critical sector effectively.

We have evaluated the ever changing epidemiology of cancers in Fars province, Iran since the re-establishment of Fars cancer registry. Based on the collected data from all related sources in Fars province from 2007–2010 we calculated the cancer age-standardized rates per 100,000 person-years (ASRs). The results are presented as incidence rates of cases by site according to the International Classification of Diseases for Oncology (ICD-O), sex, age, crude rate, and ASRs. In women the total ASR was 41.70 per 100,000 from 1985–1989 which had increased to 55.50 and 95.46 during 1998–2002 and 2007–2010. The incidence of breast cancer in women during 2007–2010 was about two and four times higher than 1998–2002 and 1985–1989. The incidence of colorectal cancer in women during 2007–2010 was about three and five times higher than 1998–2002 and 1985–1989. In men the total ASR was 62.9 per 100,000 in 1985–1989 that increased to 64.50 and 101.48 during 1998–2002 and 2007–2010. Although stomach cancer was the most common cancer among men during 1985–1989 and 1998–2002, but in recent study bladder cancer was the most common cancer among men in Fars province. The incidence of colorectal cancer in men during 2007–2010 was about three times higher than 1998–2002 and 1985–1989. This study shows growing incidence of cancer in southern Iran. The colorectal cancer in both genders had increased and its pattern is similar to western countries. In men, bladder and prostate cancers had a growing rate and the incidences of these cancers in the present study were greater than stomach cancer.

Stomach cancer, also known as gastric cancer, is a significant global health concern, exhibiting rising prevalence rates across various demographics. The Stomach Cancer and Gastric Cancer Treatment market plays a crucial role in offering vital management solutions ranging from surgical interventions to advanced chem